MedTrace Logo

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

NCT00872391 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2009-03-31

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.

Conditions

Interventions

RADIATION

Hypofractionated linear accelerator radiotherapy

10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Martin Zehetmayer, MD · Department of Ophthalmology, Medical University of Vienna, Austria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2024-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00872391 on ClinicalTrials.gov